Adverse effects of bevacizumab and their management in solid tumors

Yull Arriaga, Carlos R. Becerra

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Bevacizumab is the first successful example of targeting the vasculature for the treatment of solid tumors. Although generally well tolerated in combination with different chemotherapy regimens, bevacizumab has side effects that are unique to this class of agents. In this review, we discuss the side effects associated with bevacizumab and potential treatments to ameliorate these toxicities.

Original languageEnglish (US)
Pages (from-to)247-250
Number of pages4
JournalSupportive Cancer Therapy
Issue number4
StatePublished - Jul 2006


  • Bleeding
  • Gastrointestinal perforations
  • Hypertension
  • Proteinuria
  • Thrombosis
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Adverse effects of bevacizumab and their management in solid tumors'. Together they form a unique fingerprint.

Cite this